Organigram Global (OGI) Total Non-Current Liabilities (2019 - 2026)
Organigram Global (OGI) posted quarterly Total Non-Current Liabilities of $107.9 million for Q1 2026, down 2.85% on a QoQ basis from $111.1 million in Q4 2025.
Organigram Global (OGI) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Total Non-Current Liabilities for 6 consecutive years, with $107.9 million the latest figure, recorded in Q1 2026.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $107.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.9 million (changed N/A YoY) and the FY2025 annual result came in at $111.1 million, changed N/A from the prior year.
- Total Non-Current Liabilities fell to $107.9 million in Q1 2026 per OGI's latest filing, from $111.1 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for OGI reached as high as $149.0 million in Q3 2025 and fell as low as $72.2 million in Q3 2024.
- A 3-year average of $110.1 million and a median of $109.5 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The largest YoY upside for Total Non-Current Liabilities was 106.3% in 2025 against a maximum downside of 106.3% in 2025.
- Year by year, Total Non-Current Liabilities stood at $72.2 million in 2024, then soared by 53.88% to $111.1 million in 2025, then dropped by 2.85% to $107.9 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $107.9 million, $111.1 million, and $149.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Organigram Global | 89.89 Mn | 122.96 Mn | 28.97 Mn | 107.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 107.95 Mn |
| Dec 31, 2025 | 111.11 Mn |
| Sep 30, 2025 | 148.96 Mn |
| Sep 30, 2024 | 72.21 Mn |
| Nov 30, 2021 | -8.22 Mn |
| Aug 31, 2021 | 49.51 Mn |
| May 31, 2021 | -9.20 Mn |
| Feb 28, 2021 | 120.87 Mn |
| Nov 30, 2020 | 150.00 Mn |
| Aug 31, 2020 | 98.06 Mn |
| May 31, 2020 | 78.98 Mn |
| Feb 29, 2020 | 121.85 Mn |
| Aug 31, 2019 | 75.94 Mn |